GOING PUBLIC – Globally, investment activity by venture capitalists (VCs) and growth capitalists declined significantly in the first quarter of the year. In perspective, VCs have to deal with changed framework conditions. On the one hand, there is the new EU pharmaceutical legislation, which wants to shorten patent protection and prescribe the stockpiling of larger quantities of important drugs. On the other hand, incentives are to be set for the development of antibiotics, which could lead to new research and development in this area. A column by Sascha Berger. Read more.